The TNF alpha converting enzyme (TACE/ADAM17) is expressed in the atherosclerotic lesions of apolipoprotein E-deficient mice: Possible contribution to elevated plasma levels of soluble TNF alpha receptors


      TNF alpha converting enzyme (TACE) critically regulates the inflammatory processes as it releases from the cell surface several transmembrane proteins, including TNFα (TNF) and its receptors TNFR1 and TNFR2. We investigated the expression of TACE in atherosclerotic lesions of apolipoproteinE-deficient (apoE −/−) mice. Five-week-old apoE−/− male mice were fed a high-fat diet and examined at 5, 10, 15 and 25 weeks of age. A group of wild-type C57BL/6 mice (WT) fed the high-fat diet for 25 weeks was included. In apoE−/− mice, lesions progressed with time in both aortic sinus and arch, in which TACE immunostaining also increased particularly between 5 and 15 weeks. TACE expression was also observed in human atherosclerotic plaques. The plasma levels of soluble TNFR1 and TNFR2 rose with atherosclerosis. In the 25-week-old WT mice, no lesions were observed and the plasma levels of TNFRs were 17% of those of age-matched apoE−/− mice. Incubated aortas of 25-week-old apoE−/− mice released much higher amounts of sTNF and sTNFRs than did aortas of 5-week-old apoE−/− mice or 25-week-old WT mice. Active TACE was expressed at the surface of macrophages isolated from apoE−/− mice. In conclusion, TACE expression is associated with lesions in atherosclerosis-prone sites. Our data suggest that atherosclerotic lesions-expressing TACE may contribute to the elevated levels of circulating sTNFRs.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Atherosclerosis
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Mehta J.L.
        • Li D.Y.
        Inflammation in ischemic heart disease: Response to tissue injury or a pathogenetic villain?.
        Cardiovasc Res. 1999; 43: 291-299
        • Black R.A.
        • Rauch C.T.
        • Kozlosky C.J.
        • et al.
        A metalloproteinase disintegrin that releases tumour-necrosis factor-alpha from cells.
        Nature. 1997; 385: 729-733
        • Moss M.L.
        • Jin S.L.
        • Milla M.E.
        • et al.
        Cloning of a disintegrin metalloproteinase that processes precursor tumour-necrosis factor-alpha.
        Nature. 1997; 385: 733-736
        • Peiretti F.
        • Canault M.
        • Deprez-Beauclair P.
        • et al.
        Intracellular maturation and transport of tumor necrosis factor alpha converting enzyme.
        Exp Cell Res. 2003; 285: 278-285
        • Srour N.
        • Lebel A.
        • McMahon S.
        • et al.
        TACE/ADAM-17 maturation and activation of sheddase activity require proprotein convertase activity.
        FEBS Lett. 2003; 554: 275-283
        • Endres K.
        • Anders A.
        • Kojro E.
        • et al.
        Tumor necrosis factor-alpha converting enzyme is processed by proprotein-convertases to its mature form which is degraded upon phorbol ester stimulation.
        Eur J Biochem. 2003; 270: 2386-2393
        • Peschon J.J.
        • Slack J.L.
        • Reddy P.
        • et al.
        An essential role for ectodomain shedding in mammalian development.
        Science. 1998; 282: 1281-1284
        • Solomon K.A.
        • Pesti N.
        • Wu G.
        • et al.
        Cutting edge: a dominant negative form of TNF-alpha converting enzyme inhibits proTNF and TNFRII secretion.
        J Immunol. 1999; 163: 4105-4108
        • Reddy P.
        • Slack J.L.
        • Davis R.
        • et al.
        Functional analysis of the domain structure of tumor necrosis factor- alpha converting enzyme.
        J Biol Chem. 2000; 275: 14608-14614
        • Mezyk R.
        • Bzowska M.
        • Bereta J.
        Structure and functions of tumor necrosis factor-alpha converting enzyme.
        Acta Biochim Pol. 2003; 50: 625-645
        • Barath P.
        • Fishbein M.C.
        • Cao J.
        • et al.
        Detection and localization of tumor necrosis factor in human atheroma.
        Am J Cardiol. 1990; 65: 297-302
        • Rus H.G.
        • Niculescu F.
        • Vlaicu R.
        Tumor necrosis factor-alpha in human arterial wall with atherosclerosis.
        Atherosclerosis. 1991; 89: 247-254
        • Tipping P.G.
        • Hancock W.W.
        Production of tumor necrosis factor and interleukin-1 by macrophages from human atheromatous plaques.
        Am J Pathol. 1993; 142: 1721-1728
        • Ridker P.M.
        • Rifai N.
        • Pfeffer M.
        • et al.
        Elevation of tumor necrosis factor-{alpha} and increased risk of recurrent coronary events after myocardial infarction.
        Circulation. 2000; 101: 2149-2153
        • Skoog T.
        • Dichtl W.
        • Boquist S.
        • et al.
        Plasma tumor necrosis factor-alpha and early carotid atherosclerosis in healthy middle-aged men.
        Eur Heart J. 2002; 23: 376-383
        • Jovinge S.
        • Hamsten A.
        • Tornvall P.
        • et al.
        Evidence for a role of tumor necrosis factor alpha in disturbances of triglyceride and glucose metabolism predisposing to coronary heart disease.
        Metabolism. 1998; 47: 113-118
        • Bruunsgaard H.
        • Skinhoj P.
        • Pedersen A.N.
        • et al.
        Ageing, tumour necrosis factor-alpha (TNF-alpha) and atherosclerosis.
        Clin Exp Immunol. 2000; 121: 255-260
        • Hurlimann D.
        • Forster A.
        • Noll G.
        • et al.
        Anti-tumor necrosis factor-{alpha} treatment improves endothelial function in patients with rheumatoid arthritis.
        Circulation. 2002; 106: 2184-2187
        • Popa C.
        • Netea M.G.
        • Radstake T.
        • et al.
        Influence of anti-TNF treatment on the cardiovascular risk factors in patients with active rheumatoid arthritis.
        Ann Rheum Dis 2004: Ard. 2004; : 023119
        • Elhage R.
        • Maret A.
        • Pieraggi M-T.
        • et al.
        Differential effects of interleukin-1 receptor antagonist and tumor necrosis factor binding protein on fatty-streak formation in apolipoprotein E-deficient mice.
        Circulation. 1998; 97: 242-244
        • Niemann-Jonsson A.
        • Dimayuga P.
        • Jovinge S.
        • et al.
        Accumulation of LDL in rat arteries is associated with activation of tumor necrosis factor-alpha expression.
        Arterioscler Thromb Vasc Biol. 2000; 20: 2205-2211
        • Li A.C.
        • Brown K.K.
        • Silvestre M.J.
        • et al.
        Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice.
        J Clin Invest. 2000; 106: 523-531
        • Von Der Thusen J.H.
        • Kuiper J.
        • Fekkes M.L.
        • et al.
        Attenuation of atherogenesis by systemic and local adenovirus-mediated gene transfer of interleukin-10 in LDLr−/− mice.
        FASEB J. 2001; 15: 2730-2732
        • Zhou Z.
        • Lauer M.A.
        • Wang K.
        • et al.
        Effect of anti-tumor necrosis factor-alpha polyclonal antibody on restenosis after balloon angioplasty in a rabbit atherosclerotic model.
        Atherosclerosis. 2002; 161: 153-159
        • Canault M.
        • Peiretti F.
        • Mueller C.
        • et al.
        Exclusive expression of transmembrane TNF-[alpha] in mice reduces the inflammatory response in early lipid lesions of aortic sinus.
        Atherosclerosis. 2004; 172: 211-218
        • Branen L.
        • Hovgaard L.
        • Nitulescu M.
        • et al.
        Inhibition of tumor necrosis factor-{alpha} reduces atherosclerosis in apolipoprotein E knockout mice.
        Arterioscler Thromb Vasc Biol. 2004; 24: 2137-2142
        • Boesten L.S.
        • Zadelaar A.S.
        • van Nieuwkoop A.
        • et al.
        Tumor necrosis factor-alpha promotes atherosclerotic lesion progression in APOE*3-leiden transgenic mice.
        Cardiovasc Res. 2005; 66 (Epub 2005 Jan 28): 179-185
        • Ohta H.
        • Wada H.
        • Niwa T.
        • et al.
        Disruption of tumor necrosis factor-[alpha] gene diminishes the development of atherosclerosis in ApoE-deficient mice.
        Atherosclerosis. 2005; 180: 11-17
        • Hansen P.R.
        • Chew M.
        • Zhou J.
        • et al.
        Freunds adjuvant alone is antiatherogenic in apoE-deficient mice and specific immunization against TNFalpha confers no additional benefit.
        Atherosclerosis. 2001; 158: 87-94
        • Schreyer S.A.
        • Vick C.M.
        • LeBoeuf R.C.
        Loss of lymphotoxin-alpha but not tumor necrosis factor-alpha reduces atherosclerosis in mice.
        J Biol Chem. 2002; 277: 12364-12368
        • Beck G.
        • Bottomley G.
        • Bradshaw D.
        • et al.
        (E)-2(R)-[1(S)-(Hydroxycarbamoyl)-4-phenyl-3-butenyl]-2′-isobutyl-2′-(methanesulfonyl)-4-methylvalerohydrazide (Ro 32-7315), a selective and orally active inhibitor of tumor necrosis factor-alpha convertase.
        J Pharmacol Exp Ther. 2002; 302: 390-396
        • Reddick R.L.
        • Zhang S.H.
        • Maeda N.
        Atherosclerosis in mice lacking apo E. Evaluation of lesional development and progression.
        Arterioscler Thromb. 1994; 14: 141-147
        • Csiszar A.
        • Ungvari Z.
        • Koller A.
        • et al.
        Proinflammatory phenotype of coronary arteries promotes endothelial apoptosis in aging.
        Physiol. Genomics. 2004; 17: 21-30
        • Jovinge S.
        • Ares MPS
        • Kallin B.
        • et al.
        Human monocytes/macrophages release TNF-{alpha} in response to Ox-LDL.
        Arterioscler Thromb Vasc Biol. 1996; 16: 1573-1579
        • Rovida E.
        • Paccagnini A.
        • Del Rosso M.
        • et al.
        TNF-{{alpha}}-converting enzyme cleaves the macrophage colony-stimulating factor receptor in macrophages undergoing activation.
        J Immunol. 2001; 166: 1583-1589
        • Ermert M.
        • Pantazis C.
        • Duncker H-R.
        • et al.
        In situ localization of TNF[alpha]/[beta], TACE and TNF receptors TNF-R1 and TNF-R2 in control and LPS-treated lung tissue.
        Cytokine. 2003; 22: 89-100
        • Akatsu T.
        • Nakamura M.
        • Satoh M.
        • et al.
        Increased mRNA expression of tumour necrosis factor-alpha and its converting enzyme in circulating leucocytes of patients with acute myocardial infarction.
        Clin Sci (Lond). 2003; 105: 39-44
        • Satoh M.
        • Iwasaka J.
        • Nakamura M.
        • et al.
        Increased expression of tumor necrosis factor-alpha converting enzyme and tumor necrosis factor-alpha in peripheral blood mononuclear cells in patients with advanced congestive heart failure.
        Eur J Heart Fail. 2004; 6: 869-875
        • Aderka D.
        The potential biological and clinical significance of the soluble tumor necrosis factor receptors.
        Cytokine Growth Factor Rev. 1996; 7: 231-240
        • Porsch-Oezcueruemez M.
        • Kunz D.
        • Kloer H-U.
        • et al.
        Evaluation of serum levels of solubilized adhesion molecules and cytokine receptors in coronary heart disease.
        J Am Coll Cardiol. 1999; 34: 1995-2001
        • Benjafield A.V.
        • Wang X.L.
        • Morris B.J.
        Tumor necrosis factor receptor 2 gene (TNFRSF1B) in genetic basis of coronary artery disease.
        J Mol Med. 2001; 79: 109-115
        • Valgimigli M.
        • Ceconi C.
        • Malagutti P.
        • et al.
        Tumor necrosis factor-{alpha} receptor 1 is a major predictor of mortality and new-onset heart failure in patients with acute myocardial infarction: the cytokine-activation and long-term prognosis in myocardial infarction (C-ALPHA) study.
        Circulation. 2005; 111: 863-870
        • Douni E.
        • Kollias G.
        A Critical Role of the p75 Tumor necrosis factor receptor (p75TNF-R) in organ inflammation independent of TNF, lymphotoxin alpha, or the p55TNF-R.
        J Exp Med. 1998; 188: 1343-1352
        • Newton R.C.
        • Solomon K.A.
        • Covington M.B.
        • et al.
        Biology of TACE inhibition.
        Ann Rheum Dis. 2001; 60: 25-32
        • Canault M.
        • Peiretti F.
        • Mueller C.
        • et al.
        Proinflammatory properties of murine aortic endothelial cells exclusively expressing a non-cleavable form of TNFalpha. Effect on tumor necrosis factor alpha receptor type 2.
        Thromb Haemost. 2004; 92: 1428-1437